Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from Osaka University, Medical Department in breast cancer reported
April 3rd, 2008
"We recently established a novel assay for specific activity (SA) of cyclin-dependent kinases (CDKs) using small tumor samples (:8 MM). The aim of this study was to investigate the prognostic significance of CDK1SA and CDK2SA in human breast cancer," scientists in Suita, Japan report. "CDK1SA and CDK2SA were determined in 284 breast cancer patients and their prognostic significance was investigated. Tumors with high CDK1SA and high CDK2SA showed significantly poorer 5-year relapse-free survival than those with low CDK1 SA and low CDK2SA, respectively (66.9% vs 84.2% for CDK1SA; 43.6% vs 83.6% for CDK2SA). Moreover, combined analysis of CDK1SA and CDK2SA enabled the...
Source: Women's Health Weekly (2008-04-03)
|
